ArticleFrontiers in pharmacology2025
Changes in cultivation parameters impact cytochrome P450 gene transcription in HepaRG cells: implications for
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell line identity rather than medium composition determines transcriptomic profiles of HepaRG and HuH7 cells cultured in chemically defined or serum-based media: comparison with primary human hepatocytes.Archives of toxicology · 2026Article
- Hepatocyte Models for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of Non-HepG2 Cell Models.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The HepaRG cell line has become a widely used model for liver toxicity testing due to the expression of cytochrome P450 enzymes essential for phase I metabolism of endogenous and exogenous compounds. As variations in expression may pose human health risks, determining CYP interactions of substances is crucial in toxicity assessments. Therefore, the use of human liver cell lines, such as HepaRG, for regulatory hazard assessment requires reproducible and stable CYP enzyme expression, despite possible influencing factors, such as seeding cell number, partial cell monolayer damage, and mRNA extraction timepoint. Methods: Transcriptional changes of 12 major CYP genes in relation to changes in cultivation parameters were investigated. To this end, HepaRG cells were cultivated according to two different methods and analyzed by RT-qPCR. Cells were seeded at five densities per cultivation method and mRNA was extracted at two timepoints after completion of differentiation, also comparing extracts from undamaged and intentionally damaged cell monolayers. Results: A Bayesian regression model showed timepoint and cell number to have the most impact on transcription. Transcription was decreased at very high and very low cell numbers over recommended numbers, but this effect was strongly modulated by extraction timepoint, with transcription increasing after two additional weeks in culture. Intentional damage to the cell monolayer had marginal effects on transcription, and no evidence of an effect of cultivation method was found. Conclusion: In summary, extraction timepoint and seeding cell number are the two critical parameters to consider before initiating a CYP expression experiment with HepaRG cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.